Empowering laboratories with robust molecular analysis: Unlocking MSK-ACCESS®

SOPHiA GENETICS has launched MSK-ACCESS® powered with SOPHiA DDM™!

This decentralized version of the highly validated liquid biopsy assay developed and routinely used by Memorial Sloan Kettering Cancer Center (MSK) uses a matched tumor-normal approach to reduce noise and the risk of biological false positives. By combining MSK’s clinical expertise in cancer genomics and the robust algorithms of the SOPHiA DDM™ Platform, we can support laboratories worldwide with their precision cancer analysis capabilities.

Learning Objectives:

• Understand the advantages of using a matched tumor-normal approach to reduce noise and the risk of biological false positives.  

• Learn about the clinical implementation and benefits of MSK-ACCESS® at MSK and its evolution from version 1 to the expanded version 2.  

• Explore the analytical concordance data of MSK-ACCESS® powered with SOPHiA DDM™ for liquid biopsy. 

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

I have read and understand the Privacy Notice*

Subscribe